Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).
C. Becerra
No relevant relationships to disclose
R. Salazar
No relevant relationships to disclose
R. Garcia-Carbonero
Consultant or Advisory Role - Amgen (B); Merck (B); Pfizer (B); Roche (B)
Honoraria - Amgen (B); Merck (B); Pfizer (B); Roche (B)
Research Funding - Amgen (B); Merck (B); Pfizer (B); Roche (B)
Other Remuneration - Amgen (B); Merck (B); Pfizer (B); Roche (B)
A. L. Thomas
No relevant relationships to disclose
F. Vázquez-Mazón
No relevant relationships to disclose
J. Cassidy
Research Funding - AstraZeneca
T. Maughan
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
M. Gallén
No relevant relationships to disclose
T. Iveson
Honoraria - Pfizer; Roche
Research Funding - Pfizer; Roche
Other Remuneration - Roche
M. Hixon
Research Funding - Pfizer
A. Gualberto
Research Funding - Pfizer
D. Yin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
E. K. Bergsland
No relevant relationships to disclose
D. Li
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer